310 related articles for article (PubMed ID: 33789592)
21. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
22. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Kasner SE; Swaminathan B; Lavados P; Sharma M; Muir K; Veltkamp R; Ameriso SF; Endres M; Lutsep H; Messé SR; Spence JD; Nedeltechev K; Perera K; Santo G; Olavarria V; Lindgren A; Bangdiwala S; Shoamanesh A; Berkowitz SD; Mundl H; Connolly SJ; Hart RG;
Lancet Neurol; 2018 Dec; 17(12):1053-1060. PubMed ID: 30274772
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
25. Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source - Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
Toyoda K; Uchiyama S; Hagihara Y; Kuwashiro T; Mori T; Kamiyama K; Urano Y; Taniguchi A; Nozaki K; Cronin L; Grauer C; Brueckmann M; Diener HC
Circ J; 2020 Nov; 84(12):2286-2295. PubMed ID: 33132228
[TBL] [Abstract][Full Text] [Related]
26. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
[TBL] [Abstract][Full Text] [Related]
27. Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Shoamanesh A; Hart RG; Connolly SJ; Kasner SE; Smith EE; Martí-Fàbregas J; Liu YY; Uchiyama S; Mikulik R; Veltkamp R; O'Donnell MJ; Ntaios G; Muir KW; Field TS; Santo GC; Olavarria V; Mundl H; Lutsep H; Berkowitz SD; Sharma M
JAMA Neurol; 2021 Jan; 78(1):11-20. PubMed ID: 33074284
[TBL] [Abstract][Full Text] [Related]
28. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
[TBL] [Abstract][Full Text] [Related]
29. Review and update of the concept of embolic stroke of undetermined source.
Diener HC; Easton JD; Hart RG; Kasner S; Kamel H; Ntaios G
Nat Rev Neurol; 2022 Aug; 18(8):455-465. PubMed ID: 35538232
[TBL] [Abstract][Full Text] [Related]
30. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Diener HC; Easton JD; Granger CB; Cronin L; Duffy C; Cotton D; Brueckmann M; Sacco RL;
Int J Stroke; 2015 Dec; 10(8):1309-12. PubMed ID: 26420134
[TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.
Martinez-Majander N; Ntaios G; Liu YY; Ylikotila P; Joensuu H; Saarinen J; Perera KS; Marti-Fabregas J; Chamorro A; Rudilosso S; Prats-Sanchez L; Berkowitz SD; Mundl H; Themeles E; Tiainen M; Demchuk A; Kasner SE; Hart RG; Tatlisumak T;
Eur J Neurol; 2020 May; 27(5):841-848. PubMed ID: 32056346
[TBL] [Abstract][Full Text] [Related]
32. The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention
.
Masbah N; Macleod MJ
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):220-230. PubMed ID: 28025962
[TBL] [Abstract][Full Text] [Related]
33. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
Lorenzoni V; Pirri S; Turchetti G
Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
[TBL] [Abstract][Full Text] [Related]
36. Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Merkler AE; Pearce LA; Kasner SE; Shoamanesh A; Birnbaum LA; Kamel H; Sheth KN; Sharma R
JAMA Neurol; 2021 Dec; 78(12):1454-1460. PubMed ID: 34694346
[TBL] [Abstract][Full Text] [Related]
37. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2012; 15(4):776-85. PubMed ID: 22449118
[TBL] [Abstract][Full Text] [Related]
38. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
[TBL] [Abstract][Full Text] [Related]
39. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
